Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
TRC102 in Combination With Chemoradiation and Durvalumab in Stage III Non-Squamous NSCLC
NCT05198830Phase 2Active, not recruiting
- Sponsor
- National Cancer Institute
- Start
- Dec 2022
- Primary completion
- Jun 2027
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of methoxyamine hydrochloride in non-small cell lung cancer (NSCLC) (2 arms), sponsored by National Cancer Institute. Primary endpoint: Progression-Free Survival at 5 years. Started Dec 2022; status: active, not recruiting.
02
Drugs
methoxyamine hydrochloride
03
Conditions
non-small cell lung cancer (NSCLC)
Beyond the preview
Go deeper on NCT05198830.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT05198830.